Abstract:AIM To observe whether the exogenous human vascular endothelial growth factor hVEGF can express and secrete endothelial growth factor EGF or not after it is guided in normal dermal fibroblasts which is the base of gene transfected artificial skin of tissue engineering as a new substitute for wound healing. METHODS This experiment was conducted in Jilin University from June 2001 to June 2005. ① The recombinant mammalian expression plasmid vector containing hVEGF cDNA pcDNA3.0-hVEGF165 was amplified in DH5a then purified and finally identified by agarose gel electrophoresis analysis after digestion with restriction endonuclease EcoRⅠand XbaⅠ.②Skin biopsies were obtained from two neonatal rabbits at the level of clean animal chipped into small pieces 0.3 cm in width. Dermal fibroblasts were isolated and cultured in vitro by digestion with collagenaseⅠ. Fibroblasts were transfected with the plasmids of pcDNA3.0-VEGF165 using lipo-mediated transfection and selected with G418 for 2 to 4 weeks. The positive clones of transfected cells were obtained and proliferated in vitro. ③The level of secreted VEGF165 protein in supernatant was determined with enzyme-linked immunosorbent assay ELISA The expression of VEGF165 mRNA in transfected cells was analyzed with in situ hybridization Flow cytometerFCM was used to detect cell cycle and apoptosis The ultrastructure of transfected dermal fibroblasts was observed with transmission electron microscopeTEM. RESULTS ①Two DNA segments about 5.4 kb and 0.57 kb in length were obtained after digestion with EcoRⅠand XbaⅠ. It was confirmed that the obtained vector was the recombinant plasmid pcDNA3.0-VEGF165. ②The G418-resistant colonies were pooled to generate the stable transfected cells in all 35 wells in 15 transfecting tests. It indicated that the pcDNA3.0-VEGF165 could be efficiently introduced into dermal fibroblasts using lipo-mediated transfection. ③When hVEGF165 detected with ELISA in cell culture there was a high level of hVEGF165 expressed by transfected fibroblasts in 24 hours (3 280±2 054 ng/L) which descended gradually in 48 and 72 hours ④ In situ hybridization analysis showed that there were several positive cells expressing hVEGF mRNA in transfected fibroblasts while a mass of positive cells expressing hVEGF mRNA were found in selected fibroblasts. The clones of pcDNA3.0-hVEGF165 transfected fibroblasts could be selected successfully after treated with G418 with 2-4 weeks. ⑤FCM analysis showed that the proportion of S phase-cells increased while that of G1 phase-cells and G2 phase-cells decreased in pcDNA3.0-hVEGF165 transfected fibroblasts. It indicated that there were enhancements of both DNA synthesis and cell proliferation in the transfected cells. The apoptosis ratios of fibroblasts increased gradually which was 1.26% 2.64% and 17.35% in the groups before transfection 2 days and 12 passages after transfection respectively. ⑥The ultrastructure changes of transfected cells analyzed by TEM included many microvilli on the membrane the nucleus in curved shapes numerous rough endoplasmic reticulum and mitochondria in the cytoplasm as well as some special enveloped granues near the membrane. CONCLUSION pcDNA3.0-hVEGF165 plasmids had been transfected into fibroblasts and high level of hVEGF165 had been expressed in the transfected cells in a short period. As a new cell source it shows a good foreground in the field of gene transfected artificial skin of tissue engineering and clinical therapy for ischemic diseases and wounds healing.

Construction of Eukaryotic Expression Plasmid of Human Platelet-Derived Growth Factor-B

Construction of the Eukaryotic Expression Plasmid of Human Vascular Endothelial Growth Factor Which is Advantageous to Wound Healing

Molecular cloning and expression in Escherichia coli of human platelet-derived growth factor B chain mature peptide gene and its effects on bone tissue repair

Construction of a Eukaryotic Expression Vector Hvegf_(165)-Fused Hirudin/pcdna3.0 and Its Expression

Construction and identification of yeast expression vectors containing human platelet-derived growth factor B-chain gene]

Construction of the eukaryotic expression plasmid containing human epidermal growth factor gene with signal peptide

Cloning and Expression of Platelet-Derived Growth Factor-Chain A Gene and Purification of Expressed Product

Expression of Platelet-Derived Growth Factor B Gene Mediated by LipofectAMINE in Fibroblasts

[Molecular Cloning and Expression of Human PDGF-B Chain Mature Peptide Gene].

[Construction and Expression of Recombinant Plasmid Pcdna3.1(+) -Hhgf Available in Osteoblast].

[Effect of Expression of Platelet-Derived Growth Factor B Gene on Blood Vessel Reconstruction after Tissue Engineering Skin Grafting].

[Enhancing the Expression Level of Human Epidermal Growth Factor Using the Polyhedrin Protein Sequence of BmNPV].

Establishment and identification of small hairpin interfering RNA eukaryotic expression vectors of human platelet-derived growth factor A

Construction and identification of the recombinant prokaryotic expression vector PUC18-HGF

[Construction and Identification of Recombinant Human Platelet-Derived Growth Factor-B Adenoviral Vector and Transfection into Periodontal Ligament Stem Cells].

Construction and Identification of a Eukaryotic Expression Plasmid of Rat PDGF-C Gene

Cloning of the Gene of a Fusion Protein-Platelet Derived Growth Factor Receptor Binding Domain with Hepatitis B Core Antigen

Construction of human eukaryotic expression plasmid vascular endothelial growth factor 165 and its expression in transfected vascular smooth muscles.

Constrution of Eukaryotic Expression Vector for Human Transforming Growth Factor Β1

Construction identification and activity assay of eukaryotic expression plasmid pcDNA3.1(+)/hGDF5 containing growth/differentiation factor 5 gene

Expression of human vascular endothelial growth factor gene transfected into rabbit dermal fibroblasts in vitro